166 | LACUTAMAB IN PATIENTS WITH RELAPSED AND REFRACTORY SéZARY SYNDROME: LONG TERM FOLLOW‐UP FROM THE TELLOMAK PHASE 2 TRIAL

Documenti analoghi

• 398 | LACUTAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYCOSIS FUNGOIDES: LONG TERM FOLLOW‐UP AND TRANSLATIONAL DATA FROM THE TELLOMAK PHASE 2 TRIAL
  di: Y. H. Kim, et al.
  Pubblicazione: (2025)
• 136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL
  di: P. L. Zinzani, et al.
  Pubblicazione: (2025)
• 46 | EFFICACY OF RITUXIMAB‐BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH‐RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
  di: M. Dreyling, et al.
  Pubblicazione: (2025)
• Estudio de edad y crecimiento de la sardina fueguina (Sprattus fuegensis)de las costas de la provincia de Santa Cruz e Islas Malvinas
  di: Cousseau, M.B., et al.
  Pubblicazione: (1982)
• 833 | PRO‐MIND: PROSPECTIVE REAL‐WORLD STUDY OF TAFASITAMAB PLUS LENALIDOMIDE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN ITALY—AN ONGOING TRIAL
  di: P. L. Zinzani, et al.
  Pubblicazione: (2025)